Skip to main content

Sustainability

0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Biweekly monitoring and feedbackN/A1 trial
Active Trials
NCT07153042Recruiting3,705Est. Nov 2029
Frontera Therapeutics
Frontera TherapeuticsChina - Suzhou
1 program
Sustainability of Laparoscopic Appendectomy. Variability of Determining Factors.N/A1 trial
Active Trials
NCT07457853Completed63Est. Oct 2025

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
2029
Human BioSciencesBiweekly monitoring and feedback
Frontera TherapeuticsSustainability of Laparoscopic Appendectomy. Variability of Determining Factors.

Clinical Trials (2)

Total enrollment: 3,768 patients across 2 trials

NCT07153042Human BioSciencesBiweekly monitoring and feedback

Sustainability and Precision Prevention Project

Start: Oct 2025Est. completion: Nov 20293,705 patients
N/ARecruiting
NCT07457853Frontera TherapeuticsSustainability of Laparoscopic Appendectomy. Variability of Determining Factors.

Sustainability of Laparoscopic Appendectomy. Variability of Determining Factors.

Start: Aug 2024Est. completion: Oct 202563 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 3,768 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.